Ranger Investment Management L.P. Takes Position in ADMA Biologics Inc $ADMA

Ranger Investment Management L.P. acquired a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,115,417 shares of the biotechnology company’s stock, valued at approximately $17,706,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ADMA. BlackRock Inc. acquired a new stake in ADMA Biologics during the 2nd quarter valued at approximately $321,037,000. State Street Corp lifted its position in shares of ADMA Biologics by 0.3% in the 4th quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock worth $248,014,000 after purchasing an additional 35,614 shares during the period. Sachem Head Capital Management LP lifted its position in shares of ADMA Biologics by 27.0% in the 4th quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock worth $207,480,000 after purchasing an additional 2,415,000 shares during the period. Westfield Capital Management Co. LP boosted its stake in shares of ADMA Biologics by 36.9% in the 4th quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock valued at $127,551,000 after purchasing an additional 1,886,105 shares during the last quarter. Finally, Capital Research Global Investors boosted its stake in shares of ADMA Biologics by 104.0% in the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after purchasing an additional 3,383,559 shares during the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ADMA. Zacks Research cut shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 4th. Canaccord Genuity Group dropped their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Wall Street Zen cut shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a report on Thursday, June 18th. Finally, Raymond James Financial started coverage on ADMA Biologics in a research report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 price objective for the company. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $18.67.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $9.84 on Monday. The company has a market cap of $2.20 billion, a price-to-earnings ratio of 14.06 and a beta of 0.74. ADMA Biologics Inc has a 52 week low of $7.21 and a 52 week high of $20.46. The company has a quick ratio of 3.81, a current ratio of 6.97 and a debt-to-equity ratio of 0.49. The firm has a 50 day moving average of $8.96 and a 200-day moving average of $10.75.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, meeting the consensus estimate of $0.16. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The company had revenue of $124.39 million during the quarter, compared to analyst estimates of $125.34 million. During the same quarter in the previous year, the business posted $0.14 EPS. ADMA Biologics’s revenue for the quarter was up 2.0% compared to the same quarter last year. On average, equities analysts forecast that ADMA Biologics Inc will post 0.78 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.